Joint with: Cardiometabolism in Health and Disease
Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects
January 26-29, 2026 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Lora K. Heisler, James Trevaskis, Michael A Cowley and Matthias H. Tschöp
In Person
On Demand
January 26-29, 2026 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Lora K. Heisler, James Trevaskis, Michael A Cowley and Matthias H. Tschöp
Available Formats:
In Person
On Demand
Supported by the Directors' Fund
Available Formats: = In Person = On Demand
Monday, January 26, 2026
Booking Function
Merchandise Options
Registration Options
Registration
4:00–8:00 PM
Welcome Mixer
6:00–8:00 PM
Tuesday, January 27, 2026
Breakfast
7:00–8:00 AM
Welcome and Keynote Address (Joint)
8:00–9:00 AM
Jens Juul Holst †, University of Copenhagen the Panum Institute
GLP-1: Clinical Impact- Hits and Misses
GLP-1: Clinical Impact- Hits and Misses
Beyond Weight Loss: Applications of Obesity Medications to Other Indications (Joint)
9:00–11:15 AM
Rachel J. Roth Flach †, Pfizer Inc.
Targeting Metabolism for HFpEF
Targeting Metabolism for HFpEF
Susan Quaggin †, Northwestern University
A United Vision for Kidney and Cardiovascular Disease Treatment
A United Vision for Kidney and Cardiovascular Disease Treatment
James Trevaskis, Eli Lilly
Incretins for MASH Treatment
Incretins for MASH Treatment
Short Talk(s) Chosen from Abstracts
Coffee Break
9:30–9:50 AM
On Own for Lunch
11:15–5:00 PM
Poster Setup
11:15–1:00 PM
Poster Viewing
1:00–10:00 PM
Symposia Spotlight 1: Emerging Therapies, Lifestyle Interventions and AI Approaches (Joint)
2:30–4:30 PM
Coffee Available
4:30–5:00 PM
Late Breaking Research on Obesity Development
5:00–7:00 PM
Ana Paula Arruda †, University of California, Berkeley
Metabolic Adaptations to Nutritional Fluctuations
Metabolic Adaptations to Nutritional Fluctuations
Jason Gill †, University of Glasgow
Racial Differences in Propensity to Obesity
Racial Differences in Propensity to Obesity
Randy J. Seeley †, University of Michigan
Body Weight Set Point
Body Weight Set Point
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Wednesday, January 28, 2026
Breakfast
7:00–8:00 AM
CNS Mechanisms of Action of Weight Loss
8:00–11:00 AM
Michael A. Cowley, Monash University
Hypothalamic Neurocircuits that Mediate Drug Actions
Hypothalamic Neurocircuits that Mediate Drug Actions
Lora K. Heisler, Rowett Institute, University of Aberdeen
Brain GPCR Targets and Circuits Controlling Food Intake
Brain GPCR Targets and Circuits Controlling Food Intake
Bei B. Zhang †, Novo Nordisk
Therapeutic and Side Effects of GLP-1 Receptor Agonists
Therapeutic and Side Effects of GLP-1 Receptor Agonists
Giuseppe D'Agostino †, University of Manchester
GIP Receptor Agonism vs. Antagonism
GIP Receptor Agonism vs. Antagonism
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Poster Setup
11:00–1:00 PM
Poster Viewing
1:00–10:00 PM
Career Roundtable (Joint)
1:30–2:45 PM
Panel Discussion: Health Implications of Widespread Online Availability of Fraudulent Obesity Medications
3:00–4:30 PM
Coffee Available
4:30–5:00 PM
Leveraging Enteroendocrine Cell Secretion
5:00–7:00 PM
Shirly Pinto †, Kallyope
Unlocking GLP-1 Expressing Cells for Novel Therapeutics
Unlocking GLP-1 Expressing Cells for Novel Therapeutics
Fiona M. Gribble †, University of Cambridge
Mechanisms Underlying Nutrient Sensing in Human Intestinal-Secreting Cells
Mechanisms Underlying Nutrient Sensing in Human Intestinal-Secreting Cells
Kevin G. Murphy †, Imperial College London
Dietary Drivers of Gut Hormone Release
Dietary Drivers of Gut Hormone Release
Short Talk(s) Chosen from Abstracts
Social Hour with Lite Bites
7:00–8:00 PM
Posters
7:30–10:00 PM
Thursday, January 29, 2026
Breakfast
7:00–8:00 AM
Emerging Therapies for Obesity and Cardiometabolic Diseases (Joint)
8:00–11:00 AM
Matthias H. Tschöp, Helmholtz Munich
Dual and Triple Co-Agonists: Past, Present and Future
Dual and Triple Co-Agonists: Past, Present and Future
Elisabeth Björk †, AstraZeneca
SGLT-1: Risks and Opportunities
SGLT-1: Risks and Opportunities
Thomas Alexander Lutz †, University of Zürich
Amylin Combinations as Obesity Therapeutics
Amylin Combinations as Obesity Therapeutics
Murielle M. Véniant-Ellison †, Amgen Inc.
GLP-1 Receptor Agonist and GIP Receptor Antagonists for Obesity Treatment
GLP-1 Receptor Agonist and GIP Receptor Antagonists for Obesity Treatment
Short Talk(s) Chosen from Abstracts
Coffee Break
9:00–9:20 AM
On Own for Lunch
11:00–5:00 PM
Symposia Spotlight 2: Leveraging Genetics
2:30–4:30 PM
Coffee Available
4:30–5:00 PM
Preservation of Muscle Mass and Function during Weight Loss
5:00–6:45 PM
Mark W. Sleeman †, Regeneron Pharmaceuticals
Strategies to Prevent Muscle Loss
Strategies to Prevent Muscle Loss
Se-Jin Lee †, Jackson Laboratory
Activin Biology: Opportunities and Open Questions
Activin Biology: Opportunities and Open Questions
Darleen A. Sandoval †, University of Colorado
Muscle Mass Preservation and Mechanisms of Muscle Loss
Muscle Mass Preservation and Mechanisms of Muscle Loss
Short Talk(s) Chosen from Abstracts
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
6:45–7:00 PM
Social Hour with Lite Bites
7:00–8:00 PM
Cash Bar
8:00–11:00 PM
Entertainment
8:00–11:00 PM
Friday, January 30, 2026
Departure
12:00–11:59 PM
Subscribe for Updates